Since its founding in 1941, the American Society for Gastrointestinal Endoscopy has been dedicated to advancing patient care and digestive health by promoting excellence and innovation in gastrointestinal endoscopy. With more than 17,000 members worldwide, ASGE promotes the highest standards for endoscopic training and practice, fosters endoscopic research, recognizes distinguished contributions to endoscopy, and is the foremost resource for endoscopic education. Visit ASGE.org for more information.
A leading provider of cancer screening and diagnostics tests, Exact Sciences helps patients and healthcare providers make timely, informed decisions before, during and after a cancer diagnosis. The company’s growing product line includes well-established brands such as Cologuard and Oncotype DX, along with innovative solutions like the Cancerguard test for multi-cancer early detection and the Oncodetect test for molecular residual disease and recurrence monitoring. Exact Sciences continues to invest in a robust pipeline of advanced cancer diagnostics aimed at improving outcomes. For more information, visit ExactSciences.com.
Exact Sciences supported the ASGE CRC Screening Project with unrestricted grants in 2023, 2024, 2025 and 2026
Ironwood Pharmaceuticals is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases. Ironwood is advancing apraglutide, a next-generation, long-acting synthetic GLP-2 analog being developed for short bowel syndrome patients who are dependent on parenteral support. In addition, Ironwood has been a pioneer in the development of LINZESS® (linaclotide), the U.S. branded prescription market leader for the treatment of irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Building upon our history of innovation, we keep patients at the heart of our R&D and commercialization efforts to reduce the burden of diseases and address significant unmet needs. Founded in 1998, Ironwood Pharmaceuticals is headquartered in Boston, Massachusetts, with a site in Basel, Switzerland. Visit www.ironwoodpharma.com for additional information.
Ironwood Pharmaceuticals supported the ASGE CRC Screening Project with funds for completion colonoscopies
Sebela Pharmaceuticals is a US pharmaceutical company with a market leading position in gastroenterology and a focus on innovation in women’s health. Braintree Laboratories, Inc., a part of Sebela Pharmaceuticals, has been the market leader in colonoscopy screening preparations for over 40 years, having invented, developed and commercialized a broad portfolio of innovative prescription colonoscopy preparations and multiple gastroenterology products. Braintree also has a pipeline of gastroenterology late-stage clinical development programs, including tegoprazan, a novel agent in phase 3 development for the treatment of acid-related gastrointestinal diseases. In addition, Sebela Women’s Health recently obtained FDA approval for Miudella®, the first non-hormonal intra-uterine device (IUD) for contraception to be approved in over 40 years. Sebela Pharmaceuticals also has LevoCept®, a hormonal IUD, in late-stage development. Sebela Pharmaceuticals has offices/operations in Roswell, Georgia, Braintree, Massachusetts, and Dublin, Ireland. Visit sebelapharma.com or call 800-874-6756 for more information.
Sebela Pharmaceuticals supported the ASGE CRC Screening Project by donating its SUTAB®, SUFLAVE® and GoLYTELY® bowel preparation products for patients who had a completion colonoscopy
